Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-2503 (86%) (ighd)-ighj201) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-

Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')- Uses, Dosage, Side Effects, Food Interaction and all others data.

Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')- is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).

Trade Name	Anti-(homo Sapiens Alpha-synuclein)humanized Monoclonal Antibody.gamma.1 Heavy Chain (1-442) (homo Sapiens Vh (ighv3-2503 (86%) (ighd)-ighj201) (8.10.4) (1-113)-homo Sapiens Ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-
Generic	Cinpanemab
Cinpanemab Other Names	Cinpanemab, Immunoglobulin g1-lambda, anti-(homo sapiens alpha-synuclein)humanized monoclonal antibody.gamma.1 heavy chain (1-442) (homo sapiens vh (ighv3-2503 (86%) (ighd)-ighj201) (8.10.4) (1-113)-homo sapiens ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-, Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo, Immunoglobulin g1, anti-(human .alpha.-synuclein) (human monoclonal biib054 .gamma.1-chain), disulfide with human monoclonal biib054 .kappa.-chain, dimer
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am